NeuroMetrix Reports that Quell Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

NeuroMetrix Reports that Quell Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

NeuroMetrix Reports that Quell Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

(NASDAQ:NURO) shares are trending higher this morning on FDA news! The stock is up more than30% in heavy trading. Price action around $4.11 as of writing this.

WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021.

https://www.globenewswire.com/news-release/2022/05/19/2447000/0/en/NeuroMetrix-Reports-that-Quell-Wearable-Neuromodulation-Device-has-Received-FDA-De-Novo-Authorization-as-First-Non-Pharmacological-Treatment-for-Fibromyalgia.html

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist